TransMedics Group Inc TMDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600
-
TransMedics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
TransMedics Reports Second Quarter 2024 Financial Results
-
TransMedics to Present at the Canaccord Genuity 44th Annual Growth Conference
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024
Trading Information
- Previous Close Price
- $144.56
- Day Range
- $152.19–160.80
- 52-Week Range
- $36.42–177.37
- Bid/Ask
- $158.47 / $159.67
- Market Cap
- $5.30 Bil
- Volume/Avg
- 2.8 Mil / 844,226
Key Statistics
- Price/Earnings (Normalized)
- 3,962.16
- Price/Sales
- 15.00
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 584
- Website
- https://www.transmedics.com
Comparables
Valuation
|
Metric
|
TMDX
|
NPCE
|
ATEC
|
|---|---|---|---|
Price/Earnings (Normalized) | 3,962.16 | — | — |
Price/Book Value | 27.92 | 19.69 | 45.88 |
Price/Sales | 15.00 | 2.56 | 1.39 |
Price/Cash Flow | 73.97 | — | — |
Price/Earnings
TMDX
NPCE
ATEC
Financial Strength
|
Metric
|
TMDX
|
NPCE
|
ATEC
|
|---|---|---|---|
Quick Ratio | 8.17 | 5.31 | 1.08 |
Current Ratio | 9.37 | 6.37 | 2.22 |
Interest Coverage | −0.03 | −2.74 | −8.06 |
Quick Ratio
TMDX
NPCE
ATEC
Profitability
|
Metric
|
TMDX
|
NPCE
|
ATEC
|
|---|---|---|---|
Return on Assets (Normalized) | 3.24% | −20.21% | −9.32% |
Return on Equity (Normalized) | 15.23% | −123.13% | −562.13% |
Return on Invested Capital (Normalized) | 3.23% | −16.47% | −8.81% |
Return on Assets
TMDX
NPCE
ATEC
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Vcqrbqxjk | Ncxwcm | $195.6 Bil | |||
| Stryker Corp
SYK
| Wysbcbrkh | Ryvdc | $137.3 Bil | |||
| Boston Scientific Corp
BSX
| Yltfvclzy | Nqysrh | $122.7 Bil | |||
| Medtronic PLC
MDT
| Vytvlfht | Bfhvh | $114.6 Bil | |||
| Edwards Lifesciences Corp
EW
| Bywlswmxdc | Fvrryjn | $40.1 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Ztxb | Ywsb | $30.7 Bil | |||
| DexCom Inc
DXCM
| Xpnnnhpnp | Gzcnc | $27.0 Bil | |||
| Steris PLC
STE
| Sblzvkk | Ssbkxf | $23.6 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Vkpzsdmcwl | Fkbq | $22.0 Bil | |||
| Insulet Corp
PODD
| Zvbcmbtf | Wplly | $16.3 Bil |
United States